On October 9, 2026, Lunai Bioworks, Inc. (the "Company") submitted a formal request to The Nasdaq Stock Market LLC ("Nasdaq") asking Nasdaq to immediately suspend trading in the Company’s common stock to protect investors while Nasdaq, FINRA and other appropriate authorities assess the trading records described in the Company’s submission. The records concern trading activity that is the subject of the Company’s pending litigation, Lunai Bioworks, Inc. v. Seven Points Capital LLC et al., Case No. 1:26-cv-00549-CFC, in the United States District Court for the District of Delaware.

 

The request is based on records obtained through court-ordered discovery and described in the Company’s Second Amended Complaint filed on August 26, 2026. The submission to Nasdaq describes substantial short selling, locate deficiencies, concentrated failures to deliver and other trading information that, in the Company’s view, raise serious questions about whether trading in its common stock has occurred in a fair and orderly market. The litigation remains pending, and the allegations made by the Company have not yet been adjudicated.

 

The Company expressed concern that continued trading before those records have been reviewed leaves investors exposed to the risk of further activity of the kind alleged in the litigation. It asked Nasdaq to treat the request as urgent and promptly determine whether continued trading is consistent with a fair and orderly market, including whether an immediate suspension or other protective action is appropriate. The Company also requested confirmation of receipt and an opportunity to discuss the matter with Nasdaq MarketWatch as soon as possible, and stated that it and its counsel would be available to provide the underlying records and any additional information Nasdaq requires, subject to the protective order in the litigation. As of the filing of this Current Report, the Company has submitted its request but has not received a decision from Nasdaq. The request itself does not halt trading, and any decision to halt or suspend trading remains with Nasdaq. The company is unable to predict when and if Nasdaq will respond to this request.

 

The Company intends to continue pursuing the pending litigation and related investigation.